Literature DB >> 26646130

Influence of Lymphadenectomy on Survival for Early-Stage Endometrial Cancer.

Jason D Wright1, Yongmei Huang, William M Burke, Ana I Tergas, June Y Hou, Jim C Hu, Alfred I Neugut, Cande V Ananth, Dawn L Hershman.   

Abstract

OBJECTIVE: To use a number of methods to control for confounding and selection bias to examine the association between lymphadenectomy and survival in a large cohort of women with endometrial cancer.
METHODS: A retrospective cohort study using the National Cancer Data Base was performed to identify women with endometrioid adenocarcinoma of the endometrium who underwent hysterectomy with or without lymphadenectomy from 1998 to 2011. Traditional regression analysis, propensity score, and an instrumental variable using regional variation in the rate of lymphadenectomy as an instrument were used to examine the association between lymphadenectomy and survival.
RESULTS: A total of 151,089 women treated at 1,336 hospitals were identified; 99,052 (65.6%) patients underwent lymphadenectomy, whereas 52,037 (34.4%) did not. In a multivariable regression model, lymphadenectomy was associated with a 16% reduction in mortality (hazard ratio [HR] 0.84, 95% confidence interval [CI] 0.81-0.87). The results were similar after adjustment for adjuvant therapy (HR 0.85, 95% CI 0.82-0.87). The results were largely unchanged and suggested that lymphadenectomy was associated with improved survival after application of a propensity score analysis. In contrast, in the instrumental variable analysis, there was not a statistically significant association between lymphadenectomy and survival (HR 0.75, 95% CI 0.53-1.06), even after adjustment for adjuvant treatment (HR 0.76, 95% CI 0.54-1.06). The results were unchanged for women with T1A and T1B tumors.
CONCLUSION: Lymphadenectomy is associated with a modest, if any, effect on survival for women with endometrial cancer.

Entities:  

Mesh:

Year:  2016        PMID: 26646130      PMCID: PMC4689634          DOI: 10.1097/AOG.0000000000001194

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  33 in total

1.  Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods.

Authors:  Thérèse A Stukel; Elliott S Fisher; David E Wennberg; David A Alter; Daniel J Gottlieb; Marian J Vermeulen
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

2.  The role of lymphadenectomy in endometrial cancer: was the ASTEC trial doomed by design and are we destined to repeat that mistake?

Authors:  R Wendel Naumann
Journal:  Gynecol Oncol       Date:  2012-04-30       Impact factor: 5.482

3.  Lymphadenectomy influences the utilization of adjuvant radiation treatment for endometrial cancer.

Authors:  Charu Sharma; Israel Deutsch; Sharyn N Lewin; William M Burke; Yaming Qiao; Xuming Sun; Clifford K Chao; Thomas J Herzog; Jason D Wright
Journal:  Am J Obstet Gynecol       Date:  2011-09-16       Impact factor: 8.661

4.  The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer.

Authors:  Junzo P Chino; Ellen Jones; Andrew Berchuck; Angeles Alvarez Secord; Laura J Havrilesky
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-06-02       Impact factor: 7.038

5.  Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer.

Authors:  Janiel M Cragun; Laura J Havrilesky; Brian Calingaert; Ingrid Synan; Angeles Alvarez Secord; John T Soper; Daniel L Clarke-Pearson; Andrew Berchuck
Journal:  J Clin Oncol       Date:  2005-02-28       Impact factor: 44.544

6.  Reducing bias in the assessment of treatment effectiveness: androgen deprivation therapy for prostate cancer.

Authors:  Yong-Fang Kuo; James E Montie; Vahakn B Shahinian
Journal:  Med Care       Date:  2012-05       Impact factor: 2.983

7.  Bias in estimating the causal hazard ratio when using two-stage instrumental variable methods.

Authors:  Fei Wan; Dylan Small; Justin E Bekelman; Nandita Mitra
Journal:  Stat Med       Date:  2015-03-20       Impact factor: 2.373

8.  Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.

Authors:  Pierluigi Benedetti Panici; Stefano Basile; Francesco Maneschi; Andrea Alberto Lissoni; Mauro Signorelli; Giovanni Scambia; Roberto Angioli; Saverio Tateo; Giorgia Mangili; Dionyssios Katsaros; Gaetano Garozzo; Elio Campagnutta; Nicoletta Donadello; Stefano Greggi; Mauro Melpignano; Francesco Raspagliesi; Nicola Ragni; Gennaro Cormio; Roberto Grassi; Massimo Franchi; Diana Giannarelli; Roldano Fossati; Valter Torri; Mariangela Amoroso; Clara Crocè; Costantino Mangioni
Journal:  J Natl Cancer Inst       Date:  2008-11-25       Impact factor: 13.506

9.  Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study.

Authors:  H Kitchener; A M C Swart; Q Qian; C Amos; M K B Parmar
Journal:  Lancet       Date:  2008-12-16       Impact factor: 79.321

10.  The National Cancer Data Base: a powerful initiative to improve cancer care in the United States.

Authors:  Karl Y Bilimoria; Andrew K Stewart; David P Winchester; Clifford Y Ko
Journal:  Ann Surg Oncol       Date:  2008-01-09       Impact factor: 5.344

View more
  7 in total

1.  Utilization of sentinel lymph node biopsy for uterine cancer.

Authors:  Jason D Wright; Stephanie Cham; Ling Chen; William M Burke; June Y Hou; Ana I Tergas; Vrunda Desai; Jim C Hu; Cande V Ananth; Alfred I Neugut; Dawn L Hershman
Journal:  Am J Obstet Gynecol       Date:  2017-02-16       Impact factor: 8.661

2.  Trends in Sentinel Lymph Node Mapping and Adjuvant Therapy in Endometrial Carcinoma.

Authors:  Natalia R Gómez-Hidalgo; Ling Chen; June Y Hou; Ana I Tergas; Caryn M St Clair; Cande V Ananth; Dawn L Hershman; Jason D Wright
Journal:  Cancer Invest       Date:  2018-03-22       Impact factor: 2.176

3.  Outcomes of Patients With Surgically and Pathologically Staged IIIA-IVB Pure Endometrioid-type Endometrial Cancer: A Taiwanese Gynecology Oncology Group (TGOG-2005) Retrospective Cohort Study (A STROBE-Compliant Article).

Authors:  Jen-Ruei Chen; Ting-Chang Chang; Hung-Chun Fu; Hei-Yu Lau; I-Hui Chen; Yu-Min Ke; Yu-Ling Liang; An-Jen Chiang; Chia-Yen Huang; Yu-Chieh Chen; Mun-Kun Hong; Yu-Chi Wang; Kuo-Feng Huang; Sheng-Mou Hsiao; Peng-Hui Wang
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

4.  Prognostic factors for tumor recurrence in endometrioid endometrial cancer stages IA and IB.

Authors:  Kyung Hee Han; Hee Seung Kim; Maria Lee; Hyun Hoon Chung; Yong Sang Song
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

5.  How to choose proper local treatment in men aged ≥75 years with cT2 localized prostate cancer?

Authors:  Kun Jin; Shi Qiu; Jiakun Li; Xiaonan Zheng; Xiang Tu; Xinyang Liao; Yan Yang; Lu Yang; Qiang Wei
Journal:  Cancer Med       Date:  2019-05-08       Impact factor: 4.452

Review 6.  Targeting Epigenetic Regulators for Endometrial Cancer Therapy: Its Molecular Biology and Potential Clinical Applications.

Authors:  Futaba Inoue; Kenbun Sone; Yusuke Toyohara; Yu Takahashi; Asako Kukita; Aki Hara; Ayumi Taguchi; Michihiro Tanikawa; Tetsushi Tsuruga; Yutaka Osuga
Journal:  Int J Mol Sci       Date:  2021-02-25       Impact factor: 5.923

7.  Clinical Impact of 18F-FDG PET/CT on the Management of Gynecologic Cancers: One Center Experience.

Authors:  Akram Al-Ibraheem; Abedallatif AlSharif; Ramiz Abu-Hijlih; Imad Jaradat; Asem Mansour
Journal:  Asia Ocean J Nucl Med Biol       Date:  2019
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.